Pictured: Signage outside Genentech's headquarters in Silicon Valley/iStock, Sundry Photography

图为基因泰克硅谷/伊斯托克总部外的标牌，各种摄影

Roche subsidiary Genentech has ended its strategic collaboration and licensing agreement for the development of allogeneic T-cell therapies with Adaptimmune Therapeutics, the UK-based biopharma announced on Friday.

总部位于英国的生物制药公司（biopharma）周五宣布，罗氏（Roche）子公司基因泰克（Genentech）终止了与Adaptimmune Therapeutics开发同种异体T细胞疗法的战略合作和许可协议。

Genentech partnered with Adaptimmune in September 2021, paying $150 million upfront and pledging $150 million more over the next five years. Accounting for additional development, regulatory and commercial milestone payments across several programs, the deal had a potential value of more than $3 billion, plus royalties..

基因泰克于2021年9月与Adaptimmune合作，预付1.5亿美元，并承诺在未来五年内再提供1.5亿美元。考虑到多个项目的额外开发、监管和商业里程碑付款，该交易的潜在价值超过30亿美元，加上版税。。

The agreement had two main components: allogeneic T-cell therapies for up to five cancer targets and personalized allogeneic T-cell-based programs. Both were still in the discovery phase at the time of the termination, according to Adaptimmune’s website.

该协议有两个主要组成部分：针对多达五个癌症靶标的同种异体T细胞疗法和基于个性化同种异体T细胞的计划。据Adaptimmune的网站称，双方在终止协议时仍处于发现阶段。

An SEC filing last week revealed that the partnership will officially terminate in 180 days, after which Adaptimmune will no longer be entitled to milestone payments, nor will it have development obligations. Beyond the upfront payment, the company has received $35 million under the collaboration.

美国证券交易委员会（SEC）上周提交的一份文件显示，该合伙关系将在180天后正式终止，此后Adaptimmune将不再有权获得里程碑付款，也不再承担开发义务。除了预付款之外，该公司还收到了3500万美元的合作资金。

Adaptimmune did not reveal a specific reason for the termination in its announcement but said that the company “remains focused” on its lead candidate afamitresgene autoleucel (afami-cel), an autologous T-cell therapy candidate that is currently being reviewed by the FDA for advanced synovial sarcoma..

Adaptimmune在其公告中没有透露终止的具体原因，但表示该公司“仍然专注于”其主要候选药物afamitresgene autoleucel（afami-cel），这是一种自体T细胞治疗候选药物，目前正在接受FDA对晚期滑膜肉瘤的审查。。

The biopharma completed its rolling Biologics License Application for afami-cel in December 2023, touting strong data from the Phase II SPEARHEAD-1 study, a single-arm, open-label study testing the investigational T-cell therapy in patients with advanced synovial sarcoma and myxoid/round cell liposarcoma.

生物制药公司于2023年12月完成了afami cel的滚动生物制剂许可证申请，吹捧了II期Spearmead-1研究的有力数据，该研究是一项单臂开放标签研究，用于测试晚期滑膜肉瘤和粘液样/圆形细胞脂肪肉瘤患者的研究性T细胞治疗。

The FDA’s verdict is due on August 4, 2024..

FDA的裁决将于2024年8月4日作出。。

Results from the study were published in The Lancet on Saturday, showing an overall response rate of 39% in patients with synovial sarcoma. More than 70% of patients developed cytokine release syndrome, though only one case was deemed to be grade 3. There were no treatment-related deaths reported.

这项研究的结果于周六发表在《柳叶刀》上，显示滑膜肉瘤患者的总体缓解率为39%。超过70%的患者出现细胞因子释放综合征，尽管只有一例被认为是3级。没有与治疗相关的死亡报告。

“We had a very valuable collaboration with our partner Genentech, and we continue to believe in the long-term potential of our iPSC-based allogeneic platform,” Adaptimmune CEO Adrian Rawcliffe said in a statement. “We have the resources to deliver afami-cel to market as planned.”

Adaptimmune首席执行官阿德里安·罗克利夫（AdrianRawcliffe）在一份声明中表示：“我们与合作伙伴基因泰克（Genentech）进行了非常有价值的合作，我们继续相信我们基于iPSC的同种异体平台的长期潜力。”。“我们有资源按计划将afami cel推向市场。”

Adaptimmune will hold an Investor Day event on April 18, during which it plans to provide more details regarding the commercial launch of afami-cel.

Adaptimmune将于4月18日举行投资者日活动，期间计划提供有关afami cel商业推出的更多细节。

For Genentech, the termination of the Adaptimmune pact comes days after it announced a 3% workforce reduction across multiple departments. Around 400 patients at the subsidiary will be affected, though no roles at its parent company Roche will be terminated, according to a spokesperson.

对于基因泰克而言，Adaptimmune协议的终止是在它宣布多个部门裁员3%的几天后。据一位发言人透露，该子公司约有400名患者将受到影响，但其母公司罗氏公司的任何职位都不会终止。

Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com.

特里斯坦·马纳拉克（TristanManalac）是一位独立的科学作家，总部位于菲律宾马尼拉。在LinkedIn上联系他，或发电子邮件给他tristan@tristanmanalac.com或tristan.manalac@biospace.com.